KRT126P: A Potential Drug Target and Biomarker (G643865)
KRT126P: A Potential Drug Target and Biomarker
Kidney failure is a serious condition that affects millions of people worldwide, leading to significant morbidity and mortality. Chronic kidney disease (CKD) is the most common cause of kidney failure, and it is characterized by a decline in kidney function over time, leading to a need for dialysis or transplantation. The development of new treatments for CKD is crucial for improving the lives of patients.
KRT126P, also known as GFR194, is a gene that encodes for a protein called KuRAS2. KuRAS2 is a non-coding RNA molecule that plays a critical role in cell signaling. It is highly expressed in the kidneys and is involved in the regulation of renal development and function.
Studies have suggested that KuRAS2 may be a potential drug target for treating CKD. Several studies have shown that inhibiting KuRAS2 activity can protect the kidneys from damage caused by diabetes, high blood pressure, and other factors.
One of the reasons for the potential of KuRAS2 as a drug target is its involvement in the regulation of cell proliferation and survival. Studies have shown that KuRAS2 plays a role in the regulation of proliferation and survival of cancer cells, and that inhibiting its activity may be an effective way to treat cancer.
In addition, KuRAS2 has also been shown to be involved in the regulation of cellular processes that are important for the development and maintenance of kidney function. For example, studies have shown that KuRAS2 plays a role in the regulation of fibrosis, a process that can contribute to the development of fibrosis in the kidneys.
Another potential mechanism by which KuRAS2 may contribute to the development of CKD is its role in the regulation of inflammation. Chronic inflammation in the kidneys can contribute to the development of CKD, and inhibiting KuRAS2 activity may be an effective way to treat inflammation-related kidney damage.
In conclusion, KRT126P is a gene that has significant potential as a drug target for treating CKD. Its involvement in the regulation of cell proliferation and survival, as well as its potential role in the regulation of inflammation, make it an attractive target for researchers to explore. Further studies are needed to determine the effectiveness of KuRAS2 inhibitors in treating CKD and to develop safe and effective drugs that can be used to treat this debilitating condition.
Protein Name: Keratin 126, Pseudogene
More Common Targets
KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17 | KRT18P19 | KRT18P22 | KRT18P23 | KRT18P24 | KRT18P27 | KRT18P28 | KRT18P29 | KRT18P31 | KRT18P33 | KRT18P34 | KRT18P4 | KRT18P40 | KRT18P41 | KRT18P42 | KRT18P44 | KRT18P48 | KRT18P49 | KRT18P5 | KRT18P50 | KRT18P51 | KRT18P55 | KRT18P59 | KRT18P6 | KRT18P62 | KRT19 | KRT19P2 | KRT19P3 | KRT2 | KRT20 | KRT222 | KRT23 | KRT24 | KRT25 | KRT26 | KRT27 | KRT28 | KRT3 | KRT31 | KRT32 | KRT33A | KRT33B | KRT34 | KRT35 | KRT36 | KRT37 | KRT38 | KRT39 | KRT4 | KRT40 | KRT42P | KRT5 | KRT6A | KRT6B | KRT6C | KRT7 | KRT7-AS | KRT71 | KRT72 | KRT73 | KRT73-AS1 | KRT74 | KRT75 | KRT76 | KRT77 | KRT78 | KRT79 | KRT8 | KRT80 | KRT81 | KRT82 | KRT83 | KRT84 | KRT85 | KRT86 | KRT87P | KRT89P | KRT8P10 | KRT8P11 | KRT8P12 | KRT8P14